COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.
FitzGerald
Garret A
GA
Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. garret@spirit.gcrc.upenn.edu
D001161:Arteriosclerosis / Q000188:drug therapy*; D001682:Biological Availability; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006207:Half-Life; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism / Q000502:physiology*; D013927:Thrombosis / Q000139:chemically induced
D016861:Cyclooxygenase Inhibitors; D011451:Prostaglandin-Endoperoxide Synthases